ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer’s Care Toward Combination Therapy Future

Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapiesNEW YORK, July 13, 2026 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) today approved a…

Read the full release →

News provided by PR Newswire.